Enovis' Fiscal Q3 Adjusted Earnings, Revenue Rise; Fiscal 2024 Guidance Updated

MT Newswires Live

Nov 06, 2024

Enovis (ENOV) reported fiscal Q3 adjusted earnings Wednesday of $0.73 per diluted share, up from $0.56 a year earlier.

Analysts polled by Capital IQ expected $0.61.

Net sales for the quarter ended Sept. 27 were $505.2 million, up from $417.5 million a year earlier.

Analysts surveyed by Capital IQ expected $504.5 million.

The medical technology firm said it now expects fiscal 2024 adjusted EPS of $2.75 to $2.80, up from its previous guidance of $2.62 to $2.77. Analysts polled by Capital IQ expect $2.70.

Revenue for the fiscal year is now projected to be $2.10 billion, the company said. That compares with a range of $2.08 billion to $2.13 billion projected previously. Analysts surveyed by Capital IQ expect $2.11 billion.

Shares of the company were up more than 3% in recent premarket activity on Wednesday.

Price: 44.62, Change: +1.31, Percent Change: +3.02

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2481677695"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481677695\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2481677695?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 19:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481677695","market":"nz","top_or_hot":-1,"title":"Enovis' Fiscal Q3 Adjusted Earnings, Revenue Rise; Fiscal 2024 Guidance Updated","media":"MT Newswires Live","content":"<html><body><p> Enovis (ENOV) reported fiscal Q3 adjusted earnings Wednesday of $0.73 per diluted share, up from $0.56 a year earlier.</p><p>Analysts polled by Capital IQ expected $0.61.</p><p>Net sales for the quarter ended Sept. 27 were $505.2 million, up from $417.5 million a year earlier.</p><p>Analysts surveyed by Capital IQ expected $504.5 million.</p><p>The medical technology firm said it now expects fiscal 2024 adjusted EPS of $2.75 to $2.80, up from its previous guidance of $2.62 to $2.77. Analysts polled by Capital IQ expect $2.70.</p><p>Revenue for the fiscal year is now projected to be $2.10 billion, the company said. That compares with a range of $2.08 billion to $2.13 billion projected previously. Analysts surveyed by Capital IQ expect $2.11 billion.</p><p>Shares of the company were up more than 3% in recent premarket activity on Wednesday.</p><p>Price: 44.62, Change: +1.31, Percent Change: +3.02</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enovis' Fiscal Q3 Adjusted Earnings, Revenue Rise; Fiscal 2024 Guidance Updated</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnovis' Fiscal Q3 Adjusted Earnings, Revenue Rise; Fiscal 2024 Guidance Updated\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-06 19:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Enovis (ENOV) reported fiscal Q3 adjusted earnings Wednesday of $0.73 per diluted share, up from $0.56 a year earlier.</p><p>Analysts polled by Capital IQ expected $0.61.</p><p>Net sales for the quarter ended Sept. 27 were $505.2 million, up from $417.5 million a year earlier.</p><p>Analysts surveyed by Capital IQ expected $504.5 million.</p><p>The medical technology firm said it now expects fiscal 2024 adjusted EPS of $2.75 to $2.80, up from its previous guidance of $2.62 to $2.77. Analysts polled by Capital IQ expect $2.70.</p><p>Revenue for the fiscal year is now projected to be $2.10 billion, the company said. That compares with a range of $2.08 billion to $2.13 billion projected previously. Analysts surveyed by Capital IQ expect $2.11 billion.</p><p>Shares of the company were up more than 3% in recent premarket activity on Wednesday.</p><p>Price: 44.62, Change: +1.31, Percent Change: +3.02</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ENOV","symbol_name":"Enovis Corporation","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2481677695","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481677695","pubTimestamp":1730894255,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Enovis  reported fiscal Q3 adjusted earnings Wednesday of $0.73 per diluted share, up from $0.56 a year earlier.Analysts polled by Capital IQ expected $0.61.Net sales for the quarter ended Sept. 27 were $505.2 million, up from $417.5 million a year earlier.Analysts surveyed by Capital IQ expected $504.5 million.The medical technology firm said it now expects fiscal 2024 adjusted EPS of $2.75 to $2.80, up from its previous guidance of $2.62 to $2.77. Analysts polled by Capital IQ expect $2.70.Revenue for the fiscal year is now projected to be $2.10 billion, the company said. That compares with a range of $2.08 billion to $2.13 billion projected previously. Analysts surveyed by Capital IQ expect $2.11 billion.Shares of the company were up more than 3% in recent premarket activity on Wednesday.Price: 44.62, Change: +1.31, Percent Change: +3.02","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ENOV":"Enovis Corporation"},"translate_title":"Enovis第三财季调整后盈利、收入增长；2024财年指引已更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENOV":0.9},"content_text":"Enovis (ENOV) reported fiscal Q3 adjusted earnings Wednesday of $0.73 per diluted share, up from $0.56 a year earlier.Analysts polled by Capital IQ expected $0.61.Net sales for the quarter ended Sept. 27 were $505.2 million, up from $417.5 million a year earlier.Analysts surveyed by Capital IQ expected $504.5 million.The medical technology firm said it now expects fiscal 2024 adjusted EPS of $2.75 to $2.80, up from its previous guidance of $2.62 to $2.77. Analysts polled by Capital IQ expect $2.70.Revenue for the fiscal year is now projected to be $2.10 billion, the company said. That compares with a range of $2.08 billion to $2.13 billion projected previously. Analysts surveyed by Capital IQ expect $2.11 billion.Shares of the company were up more than 3% in recent premarket activity on Wednesday.Price: 44.62, Change: +1.31, Percent Change: +3.02","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}